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 Plasma-cell proliferations span a wide 
spectrum, ranging from plasma-cell 
dyscrasia to overt multiple myeloma. 1,2 
Plasma-cell dyscrasia can be rather mild, 
such as that associated with the low levels 
of monoclonal protein seen in mono-
clonal gammopathy of undetermined 
signi cance. However, regardless of the 
degree of plasma-cell proliferation, renal 
manifestations are frequently the initial 
presentation of the underlying process. 
Moreover, even though the circulating 
monoclonal protein has a systemic 
outreach, and many patients may have 
extrarenal manifestations, clinical symp-
tomatology is led by prominent renal 
involvement with severe renal failure. 1,2 
Renal pathology associated with the 
presence of a paraprotein can be quite 
diverse, ranging from tubular pathology 
(such as light chain cast nephropathy or 
proximal light chain tubulopathy) to 
tubulointerstitial nephritis to glomerular 
abnormalities. 1 – 6 ' e last can be associ-
ated with extracellular deposition of the 
actual paraprotein in the form of  brillar 
or non- brillar deposits. Fibrillar deposits 
are seen in light chain-derived amyloid 
(AL) and are Congo red positive and bire-
fringent under polarized light. In contrast, 
non-fibrillar deposits are seen in light 
chain deposition disease (LCDD), are 
Congo red negative, and have a granular 
or  ‘ punctate ’ ultrastructural appearance 
(reviewed by Ronco  et al. 1 and Picken 2 ). 
In rare patients, tissue deposits can be 
derived from heavy (or light and heavy) 
chains. Therefore, the terms ‘AH’ (for 
amy loid derived from the heavy chain) 
and ‘monoclonal immunoglobulin dis-
ease’  have been coined. ' e latter term 
encompasses LCDD as well as rare entities 
such as heavy chain deposition disease 
and light and heavy chain deposition 
disease. 
 Interestingly, not every patient with 
paraprotein develops tissue deposits. 
Although the exact statistics are di3  cult 
to obtain, it is estimated that, among 
patients with multiple myeloma, only 
11 % will develop AL and only 5 % will be 
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 Paraprotein-induced renal injury is associated with diverse pathologies 
and is a common cause of renal failure. In one form, mature light 
chain deposition disease, development of mesangial nodules, 
reminiscent of those seen in diabetic nephropathy, is a characteristic 
feature universally associated with disease progression. Keeling 
and Herrera have demonstrated the development of such nodules 
 in vitro using a human mesangial cell culture model. Lessons 
learned from this model might be applicable to other types of 
glomerular sclerosis . 
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diagnosed with LCDD. 1 Moreover, while 
certain light chains are associated with 
light chain cast nephropathy ( ‘ cast form-
ers ’, or tubulopathic light chains), others 
have a3  nity to glomeruli ( ‘ glomerulo-
pathic ’ light chains) and are associated 
with AL or LCDD. It has been proposed 
that the physicochemical properties of the 
paraprotein itself may predetermine the 
type of subsequent pathology. Various 
features have been implicated, such as 
abnormalities in the primary structure of 
the paraprotein, its charge, its level of gly-
cosylation, and possibly other posttrans-
lational modifications as well. 2,7 Thus, 
certain light chains, such as   VI, are over-
represented in patients with AL. In gen-
eral,   light chains predominate in AL, 
whereas   light chains predominate in 
LCDD. Interestingly, although deposition 
of a monoclonal protein occurs in both 
AL and LCDD, the pathomechanism is 
di8 erent. Elongation of the  brils seems 
to play a role in AL, while tissue deposi-
tion in monoclonal immunoglobulin dis-
ease  appears to be associated with 
one-step precipitation. Moreover, in AL, 
accumulation of the monoclonal protein 
is associated with depletion of the extra-
cellular matrix. In contrast, in mature 
LCDD, there is striking accumulation of 
the extracellular matrix-forming nodules, 
reminiscent of those seen in diabetic 
nephropathy and membranoproliferative 
glomerulone phritis type I. Importantly, 
however, early stages of AL, as well as 
LCDD, may be inconspicuous by light 
microscopy (LM) and detectable only by 
special studies. ' us, for diagnosis as well 
as for differential diagnosis, immuno-
stains — in particular, immunofluores-
cence—are critical. 1,2,4 – 6 
 Proteinuria and renal failure dominate 
the clinical presentation. In most cases, 
renal function declines rapidly, which 
underscores the urgent need not only to 
diagnose the process early but also to 
instigate e8 ective therapy. ' us far, aggres-
sive chemotherapy has been the main 
approach to the treatment of patients with 
paraprotein. 8 – 10 Although instances of 
improvement of renal function have been 
reported, in particular in patients who 
had good renal function at the time of 
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represents the classical lesion found in 
advanced LCDD. 
 ' e article by Keeling and Herrera 11 is 
not only about peculiar mesangial altera-
tions in LCDD but actually transcends 
this topic to provide crucial insights relat-
ing to mesangial-cell pathobiology. ' e 
responses that mesangial cells can exhibit 
to various injurious agents are limited. 
' e described behavior observed when 
mesangial  cel ls  were incubated 
with certain glomerulopathic light 
chains must repeat itself when they are 
confronted with other injurious agents, at 
least to a certain extent. ' e interaction 
with glomerulopathic light chains is 
governed by purported receptors located 
on the mesangial-cell membrane. ' ese 
receptors may be shared by other 
mediators of glomerular injury. What is 
most interesting is that light chains 
isolated from patients with light chain cast 
nephropathy (that is, tubulopathic light 
chains) associated with plasma-cell 
dyscrasia do not alter mesangial homeo-
stasis, which clearly shows that they 
do not interact with mesangial-cell 
receptors. 
 Although Keeling and Herrera 11 focus 
on mesangial sclerosis associated with 
LCDD, there are also potential lessons to 
be learned about the progression of 
glomerular injury in general. Transform-
ing growth factor-  is widely increased in 
progressive renal disease and is therefore 
an attractive target for modulation of renal 
injury progression. Animal studies have 
shown (reviewed by Ma and Fogo 12 ) that 
even when sclerosis has developed, with 
accumulation of extracellular matrix, this 
lesion may be remodeled with a change in 
glomerular homeostasis. Now, Keeling 
and Herrera 11 have shown that this is pos-
sible with human mesangial cells grown 
in culture. 
 ' is seminal contribution to the under-
standing of the pathogenesis of LCDD 
is most welcome, since new therapies 
aimed at targeting key steps in the cas-
cade of events may be designed for use in 
combination with a reduction of circulat-
ing glomerulopathic light chains. ' is 
therapeutic approach may help amelio-
rate, or even totally inhibit, the progres-
sion of renal damage and allow repair 
of the damaged glomerulus. As we are 
diagnosis, many patients succumb to 
progressive renal disease despite chemo-
therapy. ' us, additional treatments are 
highly desirable. Understanding the 
pathogenesis of LCDD may help in 
designing new therapies for use in combi-
nation with a reduction of circulating 
glomerulopathic light chains. 
 ' e article by Keeling and Herrera 11 
(this issue) dissects the molecular events 
that take place in the kidneys of patients 
with LCDD using an  in vitro human 
mesangial cell culture model. ' is model 
closely reproduces events that occur  in 
vivo , as seen in renal biopsies from these 
patients. Human mesangial cells are incu-
bated with light chains puri ed from the 
urine of patients with LCDD (LCDD-
LCs), and the sequential events that 
occur are monitored with the use of a 
variety of morphologic and molecular 
techniques. 
 Crucial events in the process, clearly 
delineated in the model, include the initial 
activation of platelet-derived growth 
factor-  , resulting in mesangial-cell pro-
liferation, followed by transforming 
growth factor-  activation, leading to an 
increase in extracellular matrix and a 
negative-feedback loop inhibiting cellular 
proliferation (Figure 1). ' e main extra-
cellular matrix component deposited in 
the expanded mesangium is tenascin-C, a 
complex protein. 
 Normally, tenascin-C is destroyed pre-
dominantly by metalloproteinase-7 
(MMP-7) in combination with minor 
contributions from other MMPs, most 
notably MMP-1 and MMP-3. It is inter-
esting that MMP-7 appears to be ade-
quately produced by mesangial cells in 
LCDD, but its release from the cells is 
impaired, preventing it from reaching the 
matrix, where it normally acts on the 
deposited tenascin. It is also interesting 
that the mere addition of LCDD-LCs to 
mesangial cells in culture increased the 
expression of tenascin-C in mesangial 
nodules, 11 and this increase was even 
higher with the addition of MMP-7 and 
its inhibitor. LCDD-LCs induce pheno-
typic changes in the mesangial cells, 
which in turn secrete tenascin-C in abun-
dance. LCDD-LCs cannot be catabolized 
by mesangial cells, most likely because of 
their physicochemical properties. 
Tenascin-C and LCDD-LCs colocalize in 
the center of the mesangial nodules. As a 
result, they become entrapped and non-
degradable. ' e end result is mesangial 
expansion with formation of nodules 
containing large quantities of tenascin-C 
at their centers, the typical finding 
in nodular glomerulosclerosis, which 
Feedback
inhibition










 Figure 1  |  Proposed pathway leading to glomerular sclerosis in LCDD. ECM, extracellular 
matrix; PDGF-  , platelet-derived growth factor-  ; TGF-  , transforming growth factor-  . 
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facing a true epidemic of glomerular 
sclerosis, dissecting its pathogenesis, one 
pathway at a time, is a welcome step. We 
cannot devise effective therapies for 
glomerular sclerosis unless we know its 
pathomechanism. We need to identify 
and learn how to control the responsible 
receptors triggering the pathways to 
sclerosis. 
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 Vitamin D supplementation after 
renal transplantation: how much 
vitamin D should we prescribe ? 
 Ronen  Levi 1 and  Justin  Silver 1 
 Vitamin D deficiency is common in patients with chronic kidney disease 
after renal transplantation. Vitamin D, essential for mineral and bone 
metabolism, also has myriad beneficial autocrine effects on intact 
immune responses and defense against infection, as well as suppression 
of malignant changes. Supplementation with oral parental vitamin D 
could correct this problem. Courbebaisse  et al. define how much oral 
vitamin D to prescribe to renal allograft recipients. 
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keratinocytes? Vitamin D is critically impor-
tant for the development, growth, and main-
tenance of a healthy skeleton from birth until 
death. ' e major function of vitamin D is to 
maintain calcium homeostasis. It accom-
plishes this by increasing the e3  ciency with 
which the intestine absorbs dietary calcium. 
When there is inadequate calcium in the diet 
to satisfy the body ’ s calcium requirement, 
vitamin D and other humoral and local fac-
tors communicate to the osteoblasts that 
then signal osteoclast precursors to mature 
and dissolve the calcium stored in the bone. 2 
Vitamin D 3 is metabolized in the liver to 
produce 25-hydroxyvitamin D 3 (25(OH)D) 
and then in the kidney to 1,25-dihydroxyvi-
tamin D 3 (1,25(OH) 2 D), the biologically 
active form of the vitamin. 1,25(OH) 2 D acts 
on its receptors, the vitamin D receptors, 
which are present not only in the intestine 
and bone, but in a wide variety of other tis-
sues, including the brain, heart, stomach, 
pancreas, activated T and B lymphocytes, 
skin, and gonads. Muscle function, innate 
immunity, cellular growth and maturation, 
immunomodulation, and insulin secretion, 
as well as the regulation of calcium, phos-
phorus, and bone meta bolism, are all a8 ected 
or controlled by vitamin D ( Figure 1 ). 
1,25(OH) 2 D is one of the most potent sub-
stances to inhibit proliferation of both nor-
mal and hyperproliferative cells and induce 
them to mature. It is also recognized that 
apart from the 1,25(OH) 2 D synthesized and 
 Vitamin D is an ancient hormone identi ed 
in the ocean-driG ing organisms, the plank-
ton that evolved over 750 million years ago. 
Without plankton there would be no life, 
and phytoplankton have the essential capac-
ity not only to recycle carbon but also to 
synthesize vitamin D. The ingestion of 
plankton in the depths of the oceans pro-
vides the vitamin D content of fish, and 
hence a plentiful supply for fish-eating 
humans. In the cauldrons of time  Homo 
sapiens evolved half a billion years later, 
developed remarkable cognitive neurodevel-
opment, and retained the ability to e3  ciently 
synthesize vitamin D 3 or cholecalciferol 
when exposed to the ultraviolet B rays of 
sunlight. However, we are constrained by a 
limited opportunity to bare our bodies to the 
joys of the sun, clouded by a concern for the 
harmful e8 ects of excess ultraviolet B rays. 
Transplant patients are well advised to limit 
their exposure to the ultraviolet B rays and 
their potentially damaging e8 ects because a 
well-documented complication of immuno-
suppressive therapy is the far greater inci-
dence of skin cancers. 1 But what about the 
bene cial e8 ects of ultraviolet B in initiating 
the photosynthesis of cholecalciferol in their 
see original article on page 646
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